CL2020001901A1 - Vacunas contra virus de la gripe y usos de las mismas. - Google Patents

Vacunas contra virus de la gripe y usos de las mismas.

Info

Publication number
CL2020001901A1
CL2020001901A1 CL2020001901A CL2020001901A CL2020001901A1 CL 2020001901 A1 CL2020001901 A1 CL 2020001901A1 CL 2020001901 A CL2020001901 A CL 2020001901A CL 2020001901 A CL2020001901 A CL 2020001901A CL 2020001901 A1 CL2020001901 A1 CL 2020001901A1
Authority
CL
Chile
Prior art keywords
influenza virus
virus vaccines
polypeptides
influenza
vectors
Prior art date
Application number
CL2020001901A
Other languages
English (en)
Inventor
Ferdinand Jacobus Milder
Tina Ritschel
Boerries Brandenburg
Mandy Antonia Catharina Jongeneelen
Daphné TRUAN
Johannes Petrus Maria Langedijk
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of CL2020001901A1 publication Critical patent/CL2020001901A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En el presente documento se proporcionan polipéptidos de tallo de la hemaglutinina de la gripe, ácidos nucleicos que codifican dichos polipéptidos, vectores que comprenden dicho ácido nucleico y composiciones farmacéuticas que los comprenden, así como métodos de su uso, en particular en la prevención y/o tratamiento de infecciones por virus de la gripe.
CL2020001901A 2018-01-23 2020-07-20 Vacunas contra virus de la gripe y usos de las mismas. CL2020001901A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18152991 2018-01-23

Publications (1)

Publication Number Publication Date
CL2020001901A1 true CL2020001901A1 (es) 2020-10-23

Family

ID=61094216

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020001901A CL2020001901A1 (es) 2018-01-23 2020-07-20 Vacunas contra virus de la gripe y usos de las mismas.

Country Status (29)

Country Link
US (2) US11447526B2 (es)
EP (2) EP4119154A1 (es)
JP (1) JP7317047B2 (es)
KR (1) KR102777000B1 (es)
CN (1) CN111655284B (es)
AU (1) AU2019212180B2 (es)
BR (1) BR112020014343A2 (es)
CA (1) CA3089177A1 (es)
CL (1) CL2020001901A1 (es)
CY (1) CY1125681T1 (es)
DK (1) DK3743106T3 (es)
EA (1) EA202091769A1 (es)
ES (1) ES2926243T3 (es)
HR (1) HRP20220980T1 (es)
HU (1) HUE059545T2 (es)
IL (2) IL294797B2 (es)
LT (1) LT3743106T (es)
MX (1) MX2020007777A (es)
MY (1) MY200841A (es)
PE (1) PE20210651A1 (es)
PH (1) PH12020500569A1 (es)
PL (1) PL3743106T3 (es)
PT (1) PT3743106T (es)
RS (1) RS63526B1 (es)
SG (1) SG11202006399VA (es)
SI (1) SI3743106T1 (es)
SM (1) SMT202200354T1 (es)
WO (1) WO2019145310A1 (es)
ZA (1) ZA202004538B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3152957A1 (en) * 2019-09-05 2021-03-11 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
WO2021074286A2 (en) * 2019-10-15 2021-04-22 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
WO2021249013A1 (en) * 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Vaccine compositions, methods, and uses thereof
JP2023166633A (ja) * 2020-09-30 2023-11-22 キリンホールディングス株式会社 インフルエンザウイルス抑制用の融合タンパク質およびこれを含む医薬組成物
CN114891074B (zh) * 2022-05-10 2023-04-11 中山大学·深圳 一种季节性甲型流感通用病毒样颗粒及其制备方法与应用
CN116589566A (zh) * 2022-11-18 2023-08-15 昆明医科大学第一附属医院 一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用
GB202219228D0 (en) * 2022-12-20 2023-02-01 Glaxosmithkline Biologicals Sa Novel influenza antigens
WO2024249801A2 (en) * 2023-06-02 2024-12-05 The Scripps Research Institute Influenza estem immunogens
WO2026052773A1 (en) * 2024-09-06 2026-03-12 Sanofi Modified influenza a hemagglutinin polypeptides and nucleic acids and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
CA2192442C (en) 1994-06-10 2007-09-25 Imre Kovesdi Complementary adenoviral vector systems and cell lines
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
KR100470180B1 (ko) 1995-06-15 2005-02-04 크루셀 홀란드 비.브이. 유전자 요법에 사용할 수 있는 인간의 재조합아데노바이러스 패키징 시스템
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
EP2059532B1 (en) 2006-09-07 2012-12-26 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
CA2733218A1 (en) * 2008-07-25 2010-01-28 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
JP2012521786A (ja) 2009-03-30 2012-09-20 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
MX2011011331A (es) * 2009-05-11 2011-11-18 Crucell Holland Bv Moleculas de union humanas capaces de neutralizar el virus de la influenza h3n2 y usos de las mismas.
MX2012011300A (es) 2010-03-30 2012-11-29 Sinai School Medicine Vacunas del virus de influenza y usos de las mismas.
IN2014CN00953A (es) 2011-07-14 2015-04-10 Crucell Holland Bv
AU2012343981B2 (en) 2011-11-28 2017-09-07 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
CA2913859C (en) 2013-05-30 2021-11-30 Crucell Holland B.V. Influenza virus vaccines and uses thereof
EP3395826B1 (en) 2013-08-03 2020-10-14 Calder Biosciences Inc. Methods of making and using influenza virus hemagglutinin complexes
MX378904B (es) 2014-07-10 2025-03-10 Janssen Vaccines & Prevention Bv Vacunas para virus influenza y usos de las mismas.
SG11201610456UA (en) 2014-07-10 2017-01-27 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof

Also Published As

Publication number Publication date
PL3743106T3 (pl) 2022-11-14
IL294797A (en) 2022-09-01
EP3743106B1 (en) 2022-06-15
US20220411474A1 (en) 2022-12-29
SMT202200354T1 (it) 2022-09-14
US20200377555A1 (en) 2020-12-03
DK3743106T3 (da) 2022-09-05
CN111655284A (zh) 2020-09-11
EA202091769A1 (ru) 2020-10-16
IL275849A (en) 2020-08-31
KR102777000B1 (ko) 2025-03-10
MX2020007777A (es) 2020-09-18
SI3743106T1 (sl) 2022-10-28
RS63526B1 (sr) 2022-09-30
PH12020500569A1 (en) 2021-05-10
PE20210651A1 (es) 2021-03-26
AU2019212180A1 (en) 2020-07-16
CA3089177A1 (en) 2019-08-01
JP2021511077A (ja) 2021-05-06
EP4119154A1 (en) 2023-01-18
ES2926243T3 (es) 2022-10-24
AU2019212180B2 (en) 2025-04-03
HRP20220980T1 (hr) 2022-11-11
CN111655284B (zh) 2024-06-11
MY200841A (en) 2024-01-18
BR112020014343A2 (pt) 2020-12-08
US11905314B2 (en) 2024-02-20
WO2019145310A1 (en) 2019-08-01
ZA202004538B (en) 2023-01-25
IL294797B2 (en) 2024-06-01
IL275849B (en) 2022-09-01
US11447526B2 (en) 2022-09-20
IL294797B1 (en) 2024-02-01
LT3743106T (lt) 2022-09-26
CY1125681T1 (el) 2026-02-25
KR20200113226A (ko) 2020-10-06
PT3743106T (pt) 2022-08-24
SG11202006399VA (en) 2020-08-28
HUE059545T2 (hu) 2022-11-28
JP7317047B2 (ja) 2023-07-28
EP3743106A1 (en) 2020-12-02

Similar Documents

Publication Publication Date Title
PE20210651A1 (es) Vacunas contra virus de la gripe y usos de las mismas
MX2017000395A (es) Vacunas contra virus influenza y usos de las mismas.
MX2022002766A (es) Vacunas contra el virus de la gripe y usos de las mismas.
MX2018009917A (es) Vacuna contra el virus del zika.
MX2021007679A (es) Anticuerpos humanos para hemaglutinina de influenza.
MX2019004913A (es) Vacunas de nanoparticulas lipidicas que comprenden acido ribonucleico mensajero (arnm).
CL2018002825A1 (es) Vacuna contra vrs
MX378904B (es) Vacunas para virus influenza y usos de las mismas.
SV2018005610A (es) Derivados de oxopiridina sustituidos
MX379515B (es) Vacunas contra virus de la influenza y sus usos.
BR112012020839A2 (pt) vacinas para uso na profilaxe e tratamento de doença de vírus da influenza
WO2017191258A8 (en) INFLUENZA MRNA VACCINES
MX2018012094A (es) Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas.
BR112017000313A2 (pt) sistema para o fornecimento de uma composição para tratamento bucal, composição para tratamento bucal, método para administrar uma composição para tratamento bucal
MX2018007198A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
MX2018015749A (es) Formulacion de una vacuna peptidica.
ES2682981T3 (es) Proteínas de hemaglutinina del virus de la gripe y método de uso de las mismas
MX2017003117A (es) Particula tipo virus de flavivirus.
MX363464B (es) Vacunas contra influenza h5.
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
EP3939604A3 (en) Influenza hemagglutinin protein vaccines
PY1542559A (es) Genes de chromobacterium subtsugae
EA201991319A1 (ru) Вакцины аттенуированного свиного гриппа и способы их изготовления и применения
MX2018001298A (es) Agente inductor de inmunidad.
AR094846A1 (es) Proteínas h5 del virus de la gripe h5n1 para uso como un medicamento